Edition:
United States

Roche Holding AG (RHHBY.PK)

RHHBY.PK on OTC Markets Group

33.96USD
26 May 2017
Change (% chg)

$-0.41 (-1.19%)
Prev Close
$34.37
Open
$34.20
Day's High
$34.26
Day's Low
$33.95
Volume
1,686,227
Avg. Vol
1,117,807
52-wk High
$36.82
52-wk Low
$25.25

RHHBY.PK

Chart for RHHBY.PK

About

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas:... (more)

Overall

Beta: 0.66
Market Cap(Mil.): $236,530.09
Shares Outstanding(Mil.): 6,900.50
Dividend: 1.03
Yield (%): 3.03

Financials

  RHHBY.PK Industry Sector
P/E (TTM): 23.78 14.27 17.41
EPS (TTM): 1.43 -- --
ROI: 19.20 -7.17 -5.42
ROE: 42.66 -6.63 -4.68

Deadly brain infection in German MS patient prompts Roche investigation

(This version of the May 24th story corrects date of Ocrevus dose to April, not February, in 2nd paragraph)

May 28 2017

CORRECTED-UPDATE 1-Deadly brain infection in German MS patient prompts Roche investigation

ZURICH, May 28 A person in Germany treated with Roche Holding AG’s new multiple sclerosis drug Ocrevus has been diagnosed with an often-deadly brain infection after switching from another medication earlier this year, the Swiss drugmaker said on Wednesday.

May 28 2017

CORRECTED-UPDATE 1-Deadly brain infection in German MS patient prompts Roche investigation

ZURICH, May 24 A person in Germany treated with Roche Holding AG’s new multiple sclerosis drug Ocrevus has been diagnosed with an often-deadly brain infection after switching from another medication earlier this year, the Swiss drugmaker said on Wednesday.

May 28 2017

RPT-BRIEF-Roche says data support Esbriet use in idiopathic pulmonary fibrosis

* Says new data at ats add to body of evidence for roche's esbriet (pirfenidone) in idiopathic pulmonary fibrosis Source text for Eikon: [ID:http://www.roche.com/investors/updates/inv-update-2017-05-24.htm ] Further company coverage: (Reporting By Zurich newsroom)

May 24 2017

BRIEF-Roche says data support Esbriet use in idiopathic pulmonary fibrosis

* Says new data at ats add to body of evidence for roche's esbriet (pirfenidone) in idiopathic pulmonary fibrosis Source text for Eikon: Further company coverage: (Reporting By Zurich newsroom)

May 24 2017

UPDATE 1-Merck says test shows Keytruda improves survival for bladder cancer patients

May 17 Pivotal trial results for Merck & Co Inc's immunotherapy drug Keytruda show that it lengthened survival by three months, or nearly 40 percent, for patients with advanced bladder cancer who had stopped responding to chemotherapy.

May 17 2017

ImmunoGen drug moving ahead in single-agent, combination trials

Latest results from a mid-stage trial of ImmunoGen Inc's experimental antibody-drug conjugate show that it shrinks or stabilizes tumors in nearly half of advanced ovarian cancer patients with at least medium levels of a key biomarker whose disease has become resistant to standard chemotherapy.

May 17 2017

ImmunoGen drug moving ahead in single-agent, combination trials

May 17 Latest results from a mid-stage trial of ImmunoGen Inc's experimental antibody-drug conjugate show that it shrinks or stabilizes tumors in nearly half of advanced ovarian cancer patients with at least medium levels of a key biomarker whose disease has become resistant to standard chemotherapy.

May 17 2017

As Eylea fears fade, focus turns to Regeneron's eczema drug

Regeneron Pharmaceuticals Inc said its eczema drug Dupixent was off to a strong start and the biotech stood by its full-year sales forecast for its flagship drug Eylea even as competition heats up.

May 04 2017

Novartis, Roche back French gene therapy start-up Vivet

French gene therapy start-up Vivet Therapeutics said on Thursday it had raised 37.5 million euros ($41 million) in an initial financing round, with backing from the venture arms of Swiss drugmakers Novartis and Roche.

May 04 2017

More From Around the Web

Earnings vs. Estimates